NICE Revises Alzheimer’s Treatment Guidelines to Include Medications for Mild Disease State

The National Institute for Health and Clinical Excellence (NICE) recently recommended that general practitioners in England and Wales provide treatment for patients with mild Alzheimer’s disease; previously, NICE limited treatment to patients with moderate or severe impairment due to Alzheimer’s. Patients with mild impairment were permitted to return for reassessment only when their condition deteriorated. The new recommendation will permit individuals with mild cognitive impairment to obtain medications to reduce the symptoms. NICE guidelines recommended donepezil, galantamine, revastigmine, and memantine.

The NICE guidelines, titled “NICE Final Appraisal Determination . . .